

80. The method of claim 77, wherein said anti-CD28 antibody is immobilized on a solid surface.

81. The method of claim 77, wherein said anti-CD28 antibody is soluble.

82. The method of claim 1, wherein said T cell is activated.

83. The method of claim 1, wherein said CD28 ligand is an anti-CD28 antibody.

84. The method of claim 1, wherein said HIV-1 fusion cofactor is CXCR4.

85. The method of claim 3, wherein said anti-CD28 antibody is immobilized on a solid surface.

86. The method of claim 3, wherein said anti-CD28 antibody is soluble.

#### REMARKS

Claims 1-54 were pending in the parent application. Claims 2-54 have been cancelled without prejudice, claim 1 has been amended, and new claims 55-86 have been added. Accordingly, claims 1 and 55-86 are currently pending. For the Examiner's convenience all of the pending claims are set forth in Appendix A.


Support for the amendments to the claims can be found throughout the specification including the originally filed claims. Specifically, support for the amendments to the claims can be found at, for example, page 37, lines 33-35 of the specification.

No new matter has been added. Any amendments to and/or cancellation of the claims should in no way be construed as an acquiescence to any of the Examiner's rejections in the parent case and was done solely to expedite the prosecution of the application. Applicants reserve the right to pursue the claims as originally filed in this or a separate application(s).

CONCLUSION

Reconsideration and allowance of all the pending claims is respectfully requested. If a telephone conversation with Applicants' Attorney would expedite prosecution of the above-identified application, the Examiner is urged to call the undersigned at (617) 227-7400.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Amy E. Mandragouras', is written over a horizontal line.

Amy E. Mandragouras  
Registration No. 36,207  
Attorney for Applicants

LAHIVE & COCKFIELD, LLP  
28 State Street  
Boston, MA 02109  
(617) 227-7400  
Dated: July 21, 2000

APPENDIX A

1. A method for downregulating HIV-1 fusion cofactor expression in a T cell, comprising contacting the T cell with a CD28 ligand *in vitro*, thereby downregulating HIV-1 fusion cofactor expression in the T cell.
55. A method for downregulating CCR5 expression in a T cell, comprising contacting the T cell with a CD28 ligand *in vitro*, thereby downregulating CCR5 expression in the T cell.
56. The method of claim 55, wherein said T cell is activated.
57. The method of claim 55, wherein said CD28 ligand is an anti-CD28 antibody.
58. The method of claim 57, wherein said anti-CD28 antibody is immobilized on a solid surface.
59. The method of claim 57, wherein said anti-CD28 antibody is soluble.
60. A method for downregulating CCR5 expression in a T cell, comprising contacting the T cell with a CD28 ligand *in vivo*, thereby downregulating CCR5 expression in the T cell.
61. The method of claim 60, wherein said T cell is activated.
62. The method of claim 60, wherein said CD28 ligand is an anti-CD28 antibody.
63. The method of claim 62, wherein said anti-CD28 antibody is immobilized on a solid surface.
64. The method of claim 62, wherein said anti-CD28 antibody is soluble.
65. A method for downregulating CXCR4 expression in a T cell, comprising contacting the T cell with a CD28 ligand *in vitro*, thereby downregulating CXCR4 expression in the T cell.

66. The method of claim 65, wherein said T cell is activated.
67. The method of claim 65, wherein said CD28 ligand is an anti-CD28 antibody.
68. The method of claim 67, wherein said anti-CD28 antibody is immobilized on a solid surface.
69. The method of claim 67, wherein said anti-CD28 antibody is soluble.
70. A method for downregulating CXCR4 expression in a T cell, comprising contacting the T cell with a CD28 ligand *in vivo*, thereby downregulating CXCR4 expression in the T cell.
71. The method of claim 70, wherein said T cell is activated.
72. The method of claim 70, wherein said CD28 ligand is an anti-CD28 antibody.
73. The method of claim 72, wherein said anti-CD28 antibody is immobilized on a solid surface.
74. The method of claim 72, wherein said anti-CD28 antibody is soluble.
75. A method for downregulating HIV-1 fusion cofactor expression in a T cell, comprising contacting the T cell with a CD28 ligand *in vivo*, thereby downregulating HIV-1 fusion cofactor expression in the T cell.
76. The method of claim 75, wherein said T cell is activated.
77. The method of claim 75, wherein said CD28 ligand is an anti-CD28 antibody.
78. The method of claim 75, wherein said HIV-1 fusion cofactor is CCR5.
79. The method of claim 75, wherein said HIV-1 fusion cofactor is CXCR4.
80. The method of claim 77, wherein said anti-CD28 antibody is immobilized on a solid surface.

81. The method of claim 77, wherein said anti-CD28 antibody is soluble.
82. The method of claim 1, wherein said T cell is activated.
83. The method of claim 1, wherein said CD28 ligand is an anti-CD28 antibody.
84. The method of claim 1, wherein said HIV-1 fusion cofactor is CXCR4.
85. The method of claim 3, wherein said anti-CD28 antibody is immobilized on a solid surface.
86. The method of claim 3, wherein said anti-CD28 antibody is soluble.